Auvelity (bupropion/dextromethorphan) / Axsome Therap 
Welcome,         Profile    Billing    Logout  
 1 Disease   5 Trials   5 Trials   185 News 


«123
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  STRIDE-1: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder (clinicaltrials.gov) -  Jan 14, 2020   
    P3,  N=350, Active, not recruiting, 
    To understand how the novel mechanisms of action of AXS-05 may clinically differentiate in the treatment of MDD. Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Jan 2019 --> Mar 2020
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial completion:  GEMINI: A Trial of AXS-05 in Patients With Major Depressive Disorder (clinicaltrials.gov) -  Jan 14, 2020   
    P3,  N=327, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Jan 2019 --> Mar 2020 Active, not recruiting --> Completed
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial completion date, Trial primary completion date:  ADVANCE: Addressing Dementia Via Agitation-Centered Evaluation (clinicaltrials.gov) -  Jan 14, 2020   
    P2/3,  N=435, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Sep 2019 --> Jun 2020 | Trial primary completion date: Aug 2019 --> Jun 2020
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Enrollment closed:  GEMINI: A Trial of AXS-05 in Patients With Major Depressive Disorder (clinicaltrials.gov) -  Nov 6, 2019   
    P3,  N=300, Active, not recruiting, 
    Trial completion date: Sep 2019 --> Jun 2020 | Trial primary completion date: Aug 2019 --> Jun 2020 Recruiting --> Active, not recruiting
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial completion:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  Jun 12, 2019   
    P2,  N=58, Completed, 
    We include glutamate-targeting drugs, such as racemic ketamine, esketamine, lanicemine (AZD6765), traxoprodil (CP-101,606), EVT-101, rislenemdaz (CERC-301/MK-0657), AVP-786, AXS-05, rapastinel (formerly GLYX-13), apimostinel (NRX-1074/AGN-241660), AV-101, NRX-101, basimglurant (RO4917523), decoglurant (RG-1578/RO4995819), tulrampator (CX-1632/S-47445), and riluzole; and GABA-targeting agents, such as brexanolone (SAGE-547), ganaxolone, and SAGE-217. Active, not recruiting --> Completed
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Enrollment closed:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  May 13, 2019   
    P2,  N=60, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial completion, Enrollment change:  ASCEND: Assessing Symptomatic Clinical Episodes in Depression (clinicaltrials.gov) -  Apr 16, 2019   
    P2,  N=97, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=74 --> 97
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial completion date, Trial primary completion date:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  Jan 14, 2019   
    P2,  N=60, Recruiting, 
    Active, not recruiting --> Completed | N=74 --> 97 Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  ASCEND: Assessing Symptomatic Clinical Episodes in Depression (clinicaltrials.gov) -  Dec 11, 2018   
    P2,  N=74, Active, not recruiting, 
    Trial completion date: Jan 2019 --> May 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Enrollment open:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  Apr 2, 2018   
    P2,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019 Not yet recruiting --> Recruiting
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    New P2 trial:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  Mar 21, 2018   
    P2,  N=60, Not yet recruiting, 
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    New P2 trial:  AXS-05 Phase II Trial on Smoking Behavior (clinicaltrials.gov) -  Mar 1, 2018   
    P2,  N=60, Not yet recruiting, 
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Trial primary completion date:  ADVANCE: Addressing Dementia Via Agitation-Centered Evaluation (clinicaltrials.gov) -  Aug 19, 2017   
    P2/3,  N=435, Recruiting, 
    Trial primary completion date: Sep 2017 --> Dec 2018 Trial primary completion date: Jun 2020 --> Aug 2019